AntibioticDB

TBI-223

Oxazolidinone

TB Alliance (New York, NY, USA) and the Institute of Materia Medica (Shanghai, People’s Republic of China)

2019

Highest development stage: Phase 1 Clinical Trial (NCT04865536)
Development status: Active (as of 2023)
Gram-positive activity
Mechanism of Action/Target pathogen: Active against <i>Staphylococcus aureus</i> (first report) and <i>Mycobacterium tuberculosis</i>
Additional information: Synthetic compound; may replace linezolid in BPaL regimen to treat drug-susceptible and -resistant TB
GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13029
Source: https://journals.asm.org/doi/10.1128/aac.00035-23
Citation (1): https://journals.asm.org/doi/full/10.1128/spectrum.02451-21?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/126494519